Back to Results

Roivant Sciences Ltd (ROIV)

Featured in Bullish Trend Stocks

Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing medicines and enabling technologies. Its pipeline includes IMVT-1402 for several autoimmune and inflammatory conditions, batoclimab for thyroid eye disease, and brepocitinib for immune-mediated diseases such as dermatomyositis and non-infectious uveitis. The company’s lead program is mosliciguat, an inhaled soluble guanylate cyclase activator being studied for pulmonary hypertension associated with interstitial lung disease and related cardiopulmonary conditions. Roivant also works with drug-delivery platforms, including a lipid nanoparticle system and a ligand conjugate platform. The company was founded in 2014 and is based in London, United Kingdom.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ROIV
$26.03
-34.5% Downside
Overvalued
$47.79
20.2% Upside
Undervalued
Fair
0.0%
November 16, 2026
6.8x
3,814.0x
28.748 B
25.238 B
0.4%
80.3%
19.9
308.4%
Valuation • Fair Value

Roivant Sciences Ltd (NASDAQ-ROIV) Fair Value by Valuation Model

Review the available estimates for Roivant Sciences Ltd (NASDAQ-ROIV), including Comps Fair Value.

Primary Valuation Read

Fair Value

$26.03

Estimated downside of 34.5% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$26.03

Comparable-company valuation reference.

Analyst Price Target

$47.79

Analysts imply upside of 20.2%.

How to read these valuation models

Use the 4 available valuation references for Roivant Sciences Ltd (NASDAQ-ROIV) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Roivant Sciences Ltd (NASDAQ-ROIV)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

7.532 M

Current operating scale indicator.

Revenue Forecast

55.443 M

Forward revenue estimate.

EBITDA

-1.361 B

Current operating profitability reference.

EBITDA Forecast

-1.416 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Roivant Sciences Ltd (NASDAQ-ROIV) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Roivant Sciences Ltd (NASDAQ-ROIV)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

19.9

Relatively strong balance-sheet zone.

FCF / Net Income

308.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Roivant Sciences Ltd (NASDAQ-ROIV). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Roivant Sciences Ltd (NASDAQ-ROIV)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

59

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Roivant Sciences Ltd (NASDAQ-ROIV), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Roivant Sciences Ltd (NASDAQ-ROIV) Stock Forecast & Technical Outlook

Review Roivant Sciences Ltd (NASDAQ-ROIV) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Roivant Sciences Ltd (NASDAQ-ROIV) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Roivant Sciences Ltd (NASDAQ-ROIV) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Roivant Sciences Ltd (NASDAQ-ROIV) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Roivant Sciences Ltd (NASDAQ-ROIV) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Roivant Sciences Ltd (NASDAQ-ROIV) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Roivant Sciences Ltd (NASDAQ-ROIV)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Roivant Sciences Ltd (NASDAQ-ROIV) has a Strong Buy consensus, with 10 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 10
Hold 1
Sell 0
FAQ • Fast Investor Answers

Roivant Sciences Ltd (NASDAQ-ROIV) Stock FAQ

Data-supported answers about Roivant Sciences Ltd (NASDAQ-ROIV), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$26.03
Estimated downside 34.5%
Valuation Rating
Overvalued
Estimated downside of 34.5%
Analyst Target
$47.79
Implied upside 20.2%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Roivant Sciences Ltd (NASDAQ-ROIV) is $26.03. This implies an estimated downside of 34.5% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 34.5% versus the current market price.

The available analyst price target for Roivant Sciences Ltd (NASDAQ-ROIV) is $47.79. The analyst target implies estimated upside of 20.2%.

The current financial health read for Roivant Sciences Ltd (NASDAQ-ROIV) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Roivant Sciences Ltd (NASDAQ-ROIV) is November 16, 2026.

The latest available data indicates no current dividend yield for Roivant Sciences Ltd (NASDAQ-ROIV).

The current market capitalization listed for Roivant Sciences Ltd is 28.748 B.

The current enterprise value listed for Roivant Sciences Ltd is 25.238 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Roivant Sciences Ltd is NASDAQ-ROIV, and the stock is listed on NASDAQ.

Roivant Sciences Ltd (NASDAQ-ROIV) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Roivant Sciences Ltd is 0.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Roivant Sciences Ltd is 80.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B
EXEL NASDAQ Exelixis Inc Fair Value Overvalued Market Cap 14.453 B